http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Alnylam Pharma (ALNY) Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
-
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
-
Alnylam Pharma (ALNY) Announces FDA Approval of AMVUTTRA
-
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
-
Alnylam Pharma (ALNY) Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
-
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
-
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
-
Alnylam Pharma (ALNY) Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrah
-
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
-
Alnylam Pharma (ALNY) Reports New Positive Results from the ILLUMINATE-C Phase 3 Study of Lumasiran
-
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
-
Alnylam Pharma (ALNY) Presents 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
-
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
-
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
-
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
-
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
-
Alnylam Pharma (ALNY) Announces Retirement of Steven Paul from Board
-
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
-
Alnylam Pharma (ALNY) Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
-
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
-
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
-
Alnylam Pharma (ALNY) Files Patent Infringement Suits against Pfizer (PFE) and Moderna (MRNA)
-
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
-
Alnylam Issues 2021 Corporate Responsibility Report
-
Alnylam Pharma (ALNY) Announces FDA Acceptance of sNDA for OXLUMO for Treatment of Advanced Primary Hyperoxaluria Type 1
-
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
-
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
-
Blackstone Names Ram Jagannath Global Head of Healthcare Investing, Announces Key Healthcare Sector Promotions
-
Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP)
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
-
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
-
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
-
Alnylam Pharma (ALNY) Reports Positive 18-Month Results from HELIOS-A Phase 3 Study
-
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
-
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
-
Alnylam Pharma (ALNY) Will Report Full 18-Month HELIOS-A Phase 3 Study of Vutrisiran Results SFNP Meeting
-
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
-
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
-
Alnylam Pharma (ALNY) Reports Prelim FY21 Revenues, Provides Product Updates
-
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
-
Alnylam Pharma (ALNY) Announces Collaboration with Novartis (NVS) to Explore Targeted Therapy to Restore Liver Function
-
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
-
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
-
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
-
Alnylam Pharma (ALNY) Comments on FDA Approval of Leqvio
-
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
-
Alnylam Pharma (ALNY) Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies
-
Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
